A multilayer multimodal detection and prediction model based on explainable artificial intelligence for Alzheimer's disease
- PMID: 33514817
- PMCID: PMC7846613
- DOI: 10.1038/s41598-021-82098-3
A multilayer multimodal detection and prediction model based on explainable artificial intelligence for Alzheimer's disease
Abstract
Alzheimer's disease (AD) is the most common type of dementia. Its diagnosis and progression detection have been intensively studied. Nevertheless, research studies often have little effect on clinical practice mainly due to the following reasons: (1) Most studies depend mainly on a single modality, especially neuroimaging; (2) diagnosis and progression detection are usually studied separately as two independent problems; and (3) current studies concentrate mainly on optimizing the performance of complex machine learning models, while disregarding their explainability. As a result, physicians struggle to interpret these models, and feel it is hard to trust them. In this paper, we carefully develop an accurate and interpretable AD diagnosis and progression detection model. This model provides physicians with accurate decisions along with a set of explanations for every decision. Specifically, the model integrates 11 modalities of 1048 subjects from the Alzheimer's Disease Neuroimaging Initiative (ADNI) real-world dataset: 294 cognitively normal, 254 stable mild cognitive impairment (MCI), 232 progressive MCI, and 268 AD. It is actually a two-layer model with random forest (RF) as classifier algorithm. In the first layer, the model carries out a multi-class classification for the early diagnosis of AD patients. In the second layer, the model applies binary classification to detect possible MCI-to-AD progression within three years from a baseline diagnosis. The performance of the model is optimized with key markers selected from a large set of biological and clinical measures. Regarding explainability, we provide, for each layer, global and instance-based explanations of the RF classifier by using the SHapley Additive exPlanations (SHAP) feature attribution framework. In addition, we implement 22 explainers based on decision trees and fuzzy rule-based systems to provide complementary justifications for every RF decision in each layer. Furthermore, these explanations are represented in natural language form to help physicians understand the predictions. The designed model achieves a cross-validation accuracy of 93.95% and an F1-score of 93.94% in the first layer, while it achieves a cross-validation accuracy of 87.08% and an F1-Score of 87.09% in the second layer. The resulting system is not only accurate, but also trustworthy, accountable, and medically applicable, thanks to the provided explanations which are broadly consistent with each other and with the AD medical literature. The proposed system can help to enhance the clinical understanding of AD diagnosis and progression processes by providing detailed insights into the effect of different modalities on the disease risk.
Conflict of interest statement
The authors declare no competing interests.
Figures
Similar articles
-
XGBoost-SHAP-based interpretable diagnostic framework for alzheimer's disease.BMC Med Inform Decis Mak. 2023 Jul 25;23(1):137. doi: 10.1186/s12911-023-02238-9. BMC Med Inform Decis Mak. 2023. PMID: 37491248 Free PMC article.
-
Explainable machine learning models based on multimodal time-series data for the early detection of Parkinson's disease.Comput Methods Programs Biomed. 2023 Jun;234:107495. doi: 10.1016/j.cmpb.2023.107495. Epub 2023 Mar 23. Comput Methods Programs Biomed. 2023. PMID: 37003039
-
Random forest feature selection, fusion and ensemble strategy: Combining multiple morphological MRI measures to discriminate among healhy elderly, MCI, cMCI and alzheimer's disease patients: From the alzheimer's disease neuroimaging initiative (ADNI) database.J Neurosci Methods. 2018 May 15;302:14-23. doi: 10.1016/j.jneumeth.2017.12.010. Epub 2017 Dec 18. J Neurosci Methods. 2018. PMID: 29269320
-
Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials.Alzheimers Dement. 2017 Apr;13(4):e1-e85. doi: 10.1016/j.jalz.2016.11.007. Epub 2017 Mar 22. Alzheimers Dement. 2017. PMID: 28342697 Free PMC article. Review.
-
Artificial intelligence for diagnostic and prognostic neuroimaging in dementia: A systematic review.Alzheimers Dement. 2023 Dec;19(12):5885-5904. doi: 10.1002/alz.13412. Epub 2023 Aug 10. Alzheimers Dement. 2023. PMID: 37563912 Review.
Cited by
-
A multimodal deep learning approach for the prediction of cognitive decline and its effectiveness in clinical trials for Alzheimer's disease.Transl Psychiatry. 2024 Feb 21;14(1):105. doi: 10.1038/s41398-024-02819-w. Transl Psychiatry. 2024. PMID: 38383536 Free PMC article.
-
Machine learning-based prediction of mild cognitive impairment among individuals with normal cognitive function.Front Neurol. 2024 Feb 2;15:1352423. doi: 10.3389/fneur.2024.1352423. eCollection 2024. Front Neurol. 2024. PMID: 38370526 Free PMC article.
-
An explainable machine learning approach for Alzheimer's disease classification.Sci Rep. 2024 Feb 1;14(1):2637. doi: 10.1038/s41598-024-51985-w. Sci Rep. 2024. PMID: 38302557 Free PMC article.
-
Explaining graph convolutional network predictions for clinicians-An explainable AI approach to Alzheimer's disease classification.Front Artif Intell. 2024 Jan 8;6:1334613. doi: 10.3389/frai.2023.1334613. eCollection 2023. Front Artif Intell. 2024. PMID: 38259822 Free PMC article.
-
Multimodal classification of Alzheimer's disease and mild cognitive impairment using custom MKSCDDL kernel over CNN with transparent decision-making for explainable diagnosis.Sci Rep. 2024 Jan 20;14(1):1774. doi: 10.1038/s41598-024-52185-2. Sci Rep. 2024. PMID: 38245656 Free PMC article.
References
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
